An interventional study of Lung monitoring with the Neola device in RDS of Prematurity, Preterm Birth and Lung Diseases, sponsored by Neola Medical Inc. Not yet recruiting at 2 sites in United States. Open to participants aged 1 Day to 44 Weeks. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Neola Medical Inc · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Pivotal study to assess safety and performance of Neola®, a novel lung monitoring device for neonates
The purpose of the study is to demonstrate that the device is safe and performs as intended under anticipated use conditions.
The performance of Neola will be evaluated in terms of ability to continuously measure and display the relative lung volume and absolute oxygen gas concentration during standard NICU procedures on neonates.
34 studies on the registry are indexed under Respiratory Distress Syndrome In Premature Infants; 10 are open to participants now.
This study's planned enrollment of 22 is below the median of 45 across 29 interventional studies indexed under Respiratory Distress Syndrome In Premature Infants.
Browse Respiratory Distress Syndrome In Premature Infants studies →This is the only study on the registry with Neola Medical Inc as lead sponsor.
Counted across the registry records on this site, refreshed daily.
IInclusion criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lung monitoring with the Neola device
Device: Lung monitoring with the Neola device
Lung monitoring with the Neola device
The number of device related events including skin reactions
The primary objective of the study is to evaluate safety with regards to adverse events (AE) and in particular device related adverse events. Outcome measure: The number of device related events including skin reactions.
Time frame: 2 days
The number of serious and non-serious adverse events occurring during the trial
The primary objective of the study is to evaluate safety with regards to adverse events (AE) and in particular device related adverse events. Outcome measure: The number of serious and non-serious adverse events occurring during the trial.
Time frame: 2 days
The device's ability to continuously measure and present the clinical parameters while the neonates are in a resting state/sleeping
This endpoint will be presented as the percentage of the total resting/sleeping time that the device is able to measure the clinical parameters relative lung volume and absolute oxygen concentration.
Time frame: 7 days
The device's ability to continuously measure and present the clinical parameters during normal handling of the neonates
This endpoint will be presented as the percentage of the total handling time that the device is able to measure the clinical parameters relative lung volume and absolute oxygen concentration.
Time frame: 7 days
The adhesive performance of the probes in terms of ability to be repositioned and stay attached
The adhesive performance of the probes in terms of ability to be repositioned and stay attached. This exploratory endpoint will be evaluated the percentage of probe adhesives that were able to stay attached for the duration of the measurement session
Time frame: 7 days
Evaluate the correlation between Neola® measured clinical data and clinical data available from other monitoring devices, procedures or tests.
The endpoint will be valuated using diagnostic methods such as, but not limited to: peripheral oxygen saturation (SpO2), x-ray images, Blood gas analysis data (partial pressure of oxygen (PaO2) and carbon dioxide (PaCO2)), respiratory support settings, respiratory rate, heart rate, blood pressure.
Time frame: 7 days
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2027; primary completion for Jun 2028, 12 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Mar 2026 → Jun 2027, primary completion Dec 2026 → Jun 2028 and completion Feb 2027 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome In Premature Infants →